SCN9A and paroxysmal extreme pain disorder: Mutations of SCN9A that result in NaV1.7 gain-of-function underlie paroxysmal extreme pain disorder (PEPD) and primary erythromelalgia6, 7, whereas mutations that result in the loss of NaV1.7 function underlie ‘congenital insensitivity to pain’ (CIP)8.